Johnson & Johnson $JNJ Shares Bought by BTC Capital Management Inc.

BTC Capital Management Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 5.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 96,284 shares of the company’s stock after acquiring an additional 5,339 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of BTC Capital Management Inc.’s portfolio, making the stock its 22nd biggest position. BTC Capital Management Inc.’s holdings in Johnson & Johnson were worth $17,852,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson in the third quarter valued at $26,000. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson during the second quarter worth $27,000. Clayton Financial Group LLC purchased a new position in Johnson & Johnson in the third quarter valued at about $28,000. Semmax Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc raised its position in shares of Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after purchasing an additional 198 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on JNJ shares. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Wells Fargo & Company upped their price target on Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Morgan Stanley set a $262.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Wednesday, January 28th. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Leerink Partners raised their price target on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $233.73.

Johnson & Johnson Trading Down 0.5%

Johnson & Johnson stock opened at $243.37 on Friday. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $246.35. The company has a market cap of $586.36 billion, a P/E ratio of 22.02, a PEG ratio of 2.37 and a beta of 0.35. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.80 and a current ratio of 1.03. The firm’s 50-day moving average is $217.25 and its 200-day moving average is $196.39.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion for the quarter. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.